Inyx Will Announce 2005 Year-End Results And Conduct Investors Conference Call This Coming Monday Morning
March 30 2006 - 6:23PM
PR Newswire (US)
NEW YORK, March 30 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC
Bulletin Board: IYXI), a specialty pharmaceutical company focused
on niche drug delivery technologies and products, reported today
that it will be announcing 2005 year-end results before the stock
market opens this coming Monday, April 3, 2006. Inyx will also
conduct a conference call with investors this coming Monday morning
at 9:00 a.m. Eastern Daylight Time. Investors in the U.S. should
call the following toll-free number: 877-407-0782. Outside the
U.S., investors should call: 201-689-8567. All callers should phone
in by 8:55 a.m. EDT. The call will also be webcast by Vcall, which
can be accessed at Inyx's website: http://www.inyxgroup.com/ or at
http://www.investorcalendar.com/. For those unable to access the
call live, a replay will be available to U.S. investors at the
following toll-free number: 877-660-6853; international investors
should call: 201-612-7415. All replay callers must dial-in account
number: 286 and conference I.D.: 198099. The replay will be
available approximately two hours after the live call ends and run
through 11:59 p.m. EDT on April 7, 2006. The webcast will be
archived for 90 days on the two websites listed above. On the
conference call, Inyx senior management will review the company's
2005 operating results, discuss material business developments and
provide future guidance. About Inyx Inyx, Inc. is a specialty
pharmaceutical company with niche drug delivery technologies and
products for the treatment of respiratory, allergy, dermatological,
topical and cardiovascular conditions. Inyx focuses its expertise
on both prescription and over-the-counter pharmaceutical products,
and provides specialty pharmaceutical development and production
consulting services. In addition, Inyx is developing its own
proprietary products. The company's operations are conducted
through several wholly owned subsidiaries: Inyx USA, Ltd., based in
Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited,
which owns and operates Ashton Pharmaceuticals Ltd., all near
Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris,
Inc., based in Exton, Pennsylvania. Inyx, Inc.'s corporate offices
are in New York City. For more information, please visit:
http://www.inyxinc.com/. Safe Harbor Statements about the Inyx's
future expectations, including future revenues and earnings, and
all other statements in this press release other than historical
facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Inyx intends that
such forward-looking statements be subject to the safe harbors
created thereby. Since these statements involve risks and
uncertainties and are subject to change at any time, Inyx's actual
results could differ materially from expected results. For more
information, please contact: Jay M. Green, Executive Vice President
Inyx, Inc. DATASOURCE: Inyx, Inc. CONTACT: Jay M. Green, Executive
Vice President of Inyx, Inc., Web site: http://www.inyxinc.com/
Copyright